These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17038472)

  • 1. Pharmacoeconomics: friend or foe?
    Drummond M
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii44-7. PubMed ID: 17038472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rationale of pharmacoeconomic analysis in rheumatologic indications.
    Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interest of modelling in rheumatoid arthritis.
    Beresniak A; Dupont DM; Becker JC; Merkesdal S
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S96-101. PubMed ID: 23078913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
    van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacoeconomics of drug therapy for rheumatoid arthritis.
    Tugwell P
    Rheumatology (Oxford); 2000 Jun; 39 Suppl 1():43-7. PubMed ID: 11001379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
    Nurmohamed MT; Dijkmans BA
    Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers and pharmacoeconomics in rheumatoid arthritis: a good marriage.
    Benucci M; Infantino M; Manfredi M
    J Med Econ; 2020 Sep; 23(9):923-925. PubMed ID: 32397864
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.
    Mahlich J; Kamae I; Sruamsiri R
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):339-348. PubMed ID: 29039214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.
    van den Hout WB
    Nat Clin Pract Rheumatol; 2009 Feb; 5(2):78-9. PubMed ID: 19107111
    [No Abstract]   [Full Text] [Related]  

  • 10. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics of emerging therapies for rheumatoid arthritis. Based on a presentation by Arthur Kavanaugh, MD.
    Am J Manag Care; 1999 Jun; 5(8 Suppl):S483-7; discussion S487-8. PubMed ID: 10538856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-rheumatoid biologics and pharmacoeconomic evaluation].
    Tsutani K; Igarashi A
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():711-8. PubMed ID: 15799447
    [No Abstract]   [Full Text] [Related]  

  • 13. The pharmacoeconomics of newer therapeutics for rheumatic diseases.
    Kavanaugh A
    Rheum Dis Clin North Am; 2006 Feb; 32(1):45-56, viii. PubMed ID: 16504820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treat-to-target in rheumatoid arthritis: clinical and pharmacoeconomic considerations. Introduction.
    Turchetti G; Smolen JS; Kavanaugh A; Braun J; Pincus T; Bombardieri S
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S1. PubMed ID: 23168235
    [No Abstract]   [Full Text] [Related]  

  • 15. Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
    Khilfeh I; Guyette E; Watkins J; Danielson D; Gross D; Yeung K
    J Manag Care Spec Pharm; 2019 Apr; 25(4):461-467. PubMed ID: 30917076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics of long-term treatment of rheumatoid arthritis.
    Blumenauer B; Coyle D; Tugwell P
    Expert Opin Pharmacother; 2002 Apr; 3(4):417-22. PubMed ID: 11934345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.
    Furneri G; Mantovani LG; Belisari A; Mosca M; Cristiani M; Bellelli S; Cortesi PA; Turchetti G
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S72-84. PubMed ID: 23072761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of biologics in early rheumatoid arthritis.
    Finckh A; Bansback N; Liang MH
    Ann Intern Med; 2010 Mar; 152(5):333-4; author reply 334. PubMed ID: 20194244
    [No Abstract]   [Full Text] [Related]  

  • 20. Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Pharmacoeconomics; 2002; 20(1):61-70. PubMed ID: 11817993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.